SAN FRANCISCO, March 4, 2026 /PRNewswire/ -- The global dietary supplements market is projected to undergo an extraordinary expansion over the next decade, with multiple segments demonstrating robust growth, according to an integrated analysis of recent market reports published by Grand View Research, Inc. As health consciousness soars worldwide and preventive healthcare becomes a priority for consumers of all ages, the dietary supplements sector is poised to become one of the fastest-growing segments within the broader nutraceutical landscape.

The global dietary supplements market size was estimated at USD 209.5 billion in 2025 and is forecast to approximately double its revenue to USD 393.56 billion by 2033 - representing a compound annual growth rate (CAGR) of 8.1% from 2026 to 2033.
This remarkable growth reflects a convergence of evolving consumer behaviors, demographic shifts, and industry innovation. Key drivers of market growth include heightened awareness of nutrition's role in overall health, aging populations seeking to manage age-related conditions, and broader access to supplements across both offline and online retail channels.
Stronger Regional Markets: U.S. Leading Domestic Growth
In the United States, one of the most mature and influential markets, the dietary supplements industry is projected to grow from an estimated USD 68.74 billion in 2025 to USD 131.08 billion by 2033, posting a CAGR of 8.5% from 2026 to 2033.
U.S. consumers are increasingly proactive about managing wellness - seeking products that support immunity, energy, mental well-being, and preventative health. Multivitamins remain among the most popular supplement types accounting for a significant share of consumer use.
Identify scalable opportunities across the U.S. markets
Core Market Segments Fueling Growth
Across global and regional analyses, several segments stand out for their strong contributions to market expansion:
Vitamin supplements accounted for a 28.2% share of the global market in 2025, underscoring their foundational role in meeting consumer demand for basic nutritional and immune support.
Likewise, in the U.S. market, vitamin supplements held a 28.1% share of revenue in 2025, driven by the widespread use of multivitamins, vitamin D, and vitamin C.
Dietary supplements targeting immune health captured 11.5% share of global revenue in 2024, reflecting ongoing consumer emphasis on preventive immune support, particularly in the wake of global health concerns.
In the U.S., immunity supplements accounted for a 10.9% share of the dietary supplement revenue in 2025, illustrating the sustainability of this health trend across markets.
Stay ahead of evolving consumer health priorities with a data-driven strategy
Powdered supplements, specifically favored for customization and convenience, are anticipated to grow at a CAGR of 10.3% globally from 2025 to 2033.
In the U.S. market, powdered formats are similarly projected to grow at a 10.2% CAGR for the period from 2026 to 2033, supported by demand among fitness enthusiasts and lifestyle consumers.
End User Dynamics: Adults, Infants, and Prenatal Nutrition
Adults remain the dominant end user group in both the global and the U.S. markets:
Similarly, in the U.S., adults represented 63.3% of dietary supplements revenue in 2025.
However, other subgroups including infants and prenatal health segments are experiencing accelerated growth:
Request a customized report to align these insights with your strategic business objectives
Distribution Channel Evolution: Offline Strength Coupled with E-Commerce Growth
Despite rapid digitization, traditional offline channels (including pharmacies, health stores, supermarkets, and clinics) continue to dominate distribution:
At the same time, online sales are projected to grow vigorously:
Explore in-depth market intelligence to identify high-growth segments and emerging consumer trends
Probiotic Supplements: High-Growth Micro-Segment
Probiotic dietary supplements focused on gut and digestive health are emerging as a fast-growing niche:
This segment's growth reflects increasing consumer awareness about the link between gut health, immunity, and overall well-being.
Contract Manufacturing: Supporting Industry Infrastructure
The increase in dietary supplements demand is mirrored in the production ecosystem:
This rapid growth underscores the strategic importance of third-party manufacturing partnerships, enabling product innovation, scalable production, and broader global distribution.
Market Outlook and Industry Implications
On a global level, the Grand View Research data paints a compelling picture: the dietary supplements market is on an upward trajectory, driven by fundamental shifts in consumer behavior, health priorities, and retail dynamics. With forecasts projecting global market valuation at over USD 393.56 billion by 2033, this industry represents a major growth opportunity for manufacturers, retailers, health professionals, and investors alike.
In addition, regional markets such as the United States, which is expected to exceed USD 131 billion by 2033, highlight the significant domestic potential for targeted product development and strategic expansion.
Innovative product formats, ranging from immunity boosters to prenatal supplements and probiotic formulations, are expected to continue the increasing consumer engagement, while the evolution of e-commerce and personalized nutrition services is ensuring new pathways to market growth.
About Grand View Research
Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.
Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research. Gain insights from 30K+ Global & Regional Reports, 120K+ Country Reports, 1.2M+ Market Statistics, 200K+ Company Profiles, and 5 business solutions encompassing ESG and Sustainability Consulting, Procurement Intelligence, Pricing Index and Analysis, and Consumer Analytics.
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com
Web: https://www.grandviewresearch.com
Follow Us: LinkedIn | Twitter
Blog - https://globalindustryherald.com/
Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg

Bachem hat für das Geschäftsjahr 2025 robuste Zahlen vorgelegt und die durchschnittlichen Analystenschätzungen beim Umsatz wie beim Ergebnis übertroffen. Der Pharmazulieferer setzte 695,1 Millionen Franken um, ein Plus von 14,8 Prozent gegenüber dem Vorjahr; in Lokalwährungen lag das Wachstum sogar bei 19,2 Prozent. Im ersten Halbjahr war das Unternehmen in Lokalwährungen noch um 34 Prozent gewachsen. Unter dem Strich erzielte Bachem einen Reingewinn von 148,8 Millionen Franken und damit knapp 24 Prozent mehr als 2024. Damit lag das Unternehmen rund 30 Millionen Franken über der Konsensschätzung.
Auch auf operativer Ebene legte Bachem zu. Der EBITDA stieg um 21,8 Prozent auf 214,7 Millionen Franken, die Marge verbesserte sich um 1,8 Prozentpunkte auf 30,9 Prozent. Darin enthalten ist allerdings ein positiver Sondereffekt von 16,1 Millionen Franken aus der Standortentwicklung im Sisslerfeld sowie dem Verkauf eines Gebäudes in den USA. Bereinigt lag die EBITDA-Marge bei 28,6 Prozent und damit ungefähr auf Höhe der Markterwartungen. Aktionäre sollen an der Entwicklung teilhaben: Die Divende soll von 0,85 auf 0,90 Franken je Aktie erhöht werden.
Für Gesprächsstoff sorgt der Ausblick. Unter der neuen CEO Anne-Kathrin Stoller rückt Bachem von der bisher kommunizierten Marke eines Umsatzes von mindestens 1 Milliarde Franken ab, die 2026 erreicht werden sollte. Im aktuellen Communiqué wird dieses Mittelfristziel nicht mehr explizit erwähnt. Stattdessen stellt das Unternehmen für das laufende Jahr ein Umsatzwachstum von 35 bis 45 Prozent in Aussicht, was einer Spanne von 938 Millionen bis 1,008 Milliarden Franken entspricht. Schafft Bachem den oberen Rand, wäre die bisherige Zielmarke zwar erreicht – die weniger pointierte Formulierung dürfte aber einige Investoren veranlassen, ihre Erwartungen zu justieren.
Operativ richtet Bachem die Organisation auf weiteres Wachstum aus. 2025 investierte der Konzern 332,6 Millionen Franken über alle Standorte hinweg; im laufenden Jahr sollen die Investitionen auf über 400 Millionen Franken steigen. Hintergrund sind unter anderem mehrere Grossaufträge von Herstellern der stark nachgefragten Medikamenten zur Gewichtsreduktion. Gleichzeitig treibt Bachem den Ausbau neuer Kapazitäten voran: Die erste Bauetappe des Gebäudes K wurde Ende 2025 von der Aufsichtsbehörde Swissmedic inspiziert und freigegeben. Das Unternehmen, das Peptid-basierte Wirkstoffe für Indikationen wie Krebs, Diabetes und Fettleibigkeit liefert und parallel ein Standbein im Bereich Oligonukleotide aufbaut, setzt damit klar auf steigende Nachfrage – auch wenn es bei der kommunikativen Zuspitzung seiner Umsatzziele zurückhaltender geworden ist.